JP2022125283A5 - - Google Patents

Download PDF

Info

Publication number
JP2022125283A5
JP2022125283A5 JP2022109721A JP2022109721A JP2022125283A5 JP 2022125283 A5 JP2022125283 A5 JP 2022125283A5 JP 2022109721 A JP2022109721 A JP 2022109721A JP 2022109721 A JP2022109721 A JP 2022109721A JP 2022125283 A5 JP2022125283 A5 JP 2022125283A5
Authority
JP
Japan
Prior art keywords
amino
acrylamide
pyrimidin
isoxazolidin
methoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022109721A
Other languages
English (en)
Japanese (ja)
Other versions
JP7394298B2 (ja
JP2022125283A (ja
Filing date
Publication date
Priority claimed from PCT/KR2020/095044 external-priority patent/WO2020190119A1/ko
Application filed filed Critical
Publication of JP2022125283A publication Critical patent/JP2022125283A/ja
Publication of JP2022125283A5 publication Critical patent/JP2022125283A5/ja
Application granted granted Critical
Publication of JP7394298B2 publication Critical patent/JP7394298B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022109721A 2019-03-19 2022-07-07 ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物 Active JP7394298B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR20190031269 2019-03-19
KR10-2019-0031269 2019-03-19
KR10-2019-0134472 2019-10-28
KR20190134472 2019-10-28
PCT/KR2020/095044 WO2020190119A1 (ko) 2019-03-19 2020-03-19 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물
JP2022504023A JP7109013B2 (ja) 2019-03-19 2020-03-19 ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022504023A Division JP7109013B2 (ja) 2019-03-19 2020-03-19 ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物

Publications (3)

Publication Number Publication Date
JP2022125283A JP2022125283A (ja) 2022-08-26
JP2022125283A5 true JP2022125283A5 (https=) 2023-03-28
JP7394298B2 JP7394298B2 (ja) 2023-12-08

Family

ID=72521153

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022504023A Active JP7109013B2 (ja) 2019-03-19 2020-03-19 ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物
JP2022109721A Active JP7394298B2 (ja) 2019-03-19 2022-07-07 ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022504023A Active JP7109013B2 (ja) 2019-03-19 2020-03-19 ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物

Country Status (22)

Country Link
US (2) US12152021B2 (https=)
EP (2) EP4631507A3 (https=)
JP (2) JP7109013B2 (https=)
KR (2) KR102318875B1 (https=)
CN (3) CN114605400B (https=)
AU (2) AU2020240382B2 (https=)
BR (1) BR112021018704B1 (https=)
CA (1) CA3134261A1 (https=)
DK (1) DK3943491T3 (https=)
ES (1) ES3036467T3 (https=)
FI (1) FI3943491T3 (https=)
HU (1) HUE073283T2 (https=)
IL (2) IL299831B2 (https=)
MA (1) MA55380A (https=)
MX (1) MX2021011160A (https=)
NZ (2) NZ790920A (https=)
PL (1) PL3943491T3 (https=)
PT (1) PT3943491T (https=)
SG (1) SG11202110376XA (https=)
SI (1) SI3943491T1 (https=)
WO (1) WO2020190119A1 (https=)
ZA (1) ZA202107889B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
AU2020240382B2 (en) 2019-03-19 2022-08-25 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
TW202227425A (zh) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
KR20220085735A (ko) * 2020-12-14 2022-06-22 보로노이바이오 주식회사 아이소옥사졸리딘 유도체 화합물 및 이의 용도
EP4323356A1 (en) 2021-04-13 2024-02-21 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
EP4335847A1 (en) * 2021-05-07 2024-03-13 Voronoi Inc. Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient
CN115667251A (zh) * 2021-05-17 2023-01-31 株式会社沃若诺伊生物 杂芳基衍生物化合物、及其用途
KR102563834B1 (ko) * 2021-06-28 2023-08-04 순천대학교 산학협력단 세포자멸사를 유도하는 신규한 화합물 및 이를 포함하는 항암용 조성물
CN117430600A (zh) * 2022-07-20 2024-01-23 上海和誉生物医药科技有限公司 一种选择性egfr抑制剂及其制备方法和在药学上的应用
KR20250043424A (ko) 2022-08-05 2025-03-28 미쓰비시 마테리알 가부시키가이샤 절삭 공구
CN120035590A (zh) * 2022-11-03 2025-05-23 株式会社沃若诺伊 Egfr抑制剂的延胡索酸盐、酒石酸盐、苹果酸盐和柠檬酸盐
EP4611902A1 (en) 2022-11-03 2025-09-10 Oric Pharmaceuticals, Inc. Malonate and glycolate salts of an egfr inhibitor
AU2023381004A1 (en) * 2022-11-15 2025-04-10 Voronoi, Inc. Heteroaryl derivative compound, and uses thereof
MX2025012495A (es) * 2023-05-05 2026-02-03 Oric Pharmaceuticals Inc Inhibidor del receptor del factor de crecimiento epidérmico (egfr) para tratamiento de cánceres con mutaciones atípicas del factor de crecimiento epidérmico
WO2026080372A1 (en) 2024-10-07 2026-04-16 Oric Pharmaceuticals, Inc. Treatment of cancers comprising egfr extracellular and transmembrane mutations

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
WO2005026129A1 (en) 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
WO2006125616A2 (en) 2005-05-25 2006-11-30 Ingenium Pharmaceuticals Ag Pyrimidine-based cdk inhibitors for treating pain
TW200804364A (en) 2006-02-22 2008-01-16 Boehringer Ingelheim Int New compounds
EA200901133A1 (ru) 2007-03-20 2010-04-30 Смитклайн Бичем Корпорейшн Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
JP2011102241A (ja) 2008-03-04 2011-05-26 Dainippon Sumitomo Pharma Co Ltd 新規1−アミノカルボニルピペリジン誘導体
KR101906146B1 (ko) 2009-08-17 2018-10-10 메모리얼 슬로안-케터링 캔서 센터 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법
KR101401664B1 (ko) 2011-11-15 2014-06-11 중앙대학교 산학협력단 신경줄기세포 분화조절제용 신규 피리미딘-2,4-디아민 유도체 및 이의 의학적 용도
US8871778B2 (en) 2012-01-20 2014-10-28 Genosco Substituted pyrimidine compounds and their use as SYK inhibitors
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
WO2014055928A2 (en) 2012-10-04 2014-04-10 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
EP2769722A1 (en) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
EP2970240B1 (en) 2013-03-14 2018-01-10 Novartis AG 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EP3037424B1 (en) 2013-08-22 2017-11-08 Taiho Pharmaceutical Co., Ltd. Novel quinoline-substituted compound
BR112016008632A8 (pt) 2013-10-21 2020-03-17 Merck Patent Gmbh compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica
KR20150047855A (ko) 2013-10-25 2015-05-06 한미약품 주식회사 단백질 카이네이즈 억제 효과를 갖는 2-사이아노-아크릴아마이드 유도체
EP3143015B1 (en) 2014-05-13 2019-02-20 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN110526912B (zh) 2014-06-19 2023-02-14 武田药品工业株式会社 用于激酶抑制的杂芳基化合物
CN117069700B (zh) * 2014-10-11 2026-01-30 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
EP3929190B1 (en) * 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
EP3206691B1 (en) 2014-10-14 2018-09-19 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
CN113563332B (zh) 2014-12-23 2024-12-17 达纳-法伯癌症研究所公司 作为egfr抑制剂的新的嘧啶和治疗病症的方法
JP6970081B2 (ja) 2015-07-16 2021-11-24 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 アニリンピリミジン誘導体及びその使用
CN106478607B (zh) 2015-08-28 2019-05-24 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
US10377747B2 (en) 2015-08-31 2019-08-13 Wuxi Shuangliang Biotechnology Co., Ltd. 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof
CN108602809B (zh) 2015-12-04 2022-09-30 戴纳立制药公司 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂
EP3399968B8 (en) 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
WO2017156527A1 (en) 2016-03-11 2017-09-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
US11352352B2 (en) 2017-06-13 2022-06-07 Beijing Adamadle Biotechnology Limited Liability Company Aminopyrimidine compound, preparation method therefor and use thereof
CN111093645A (zh) * 2017-07-05 2020-05-01 Cs制药技术有限公司 Egfr酪氨酸激酶的临床上重要的突变体的选择性抑制剂
US11339157B1 (en) 2017-10-24 2022-05-24 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
TWI798334B (zh) 2018-01-31 2023-04-11 大陸商迪哲(江蘇)醫藥股份有限公司 Erbb/btk抑制劑
CN108191774B (zh) 2018-01-31 2022-05-24 中国药科大学 一类杂环化合物、其制备方法和用途
WO2019177374A1 (ko) 2018-03-13 2019-09-19 포로노이바이오 주식회사 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물
KR102782739B1 (ko) 2018-03-13 2025-03-20 보로노이 주식회사 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
US12084431B2 (en) 2018-05-14 2024-09-10 Takeda Pharmaceutical Company Limited Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
CN109280048A (zh) 2018-11-16 2019-01-29 江西科技师范大学 一种含取代苯基丙烯酰胺结构的嘧啶类化合物及其应用
CN109608394A (zh) 2018-12-03 2019-04-12 湖南大学 氮杂芳胺类化合物的合成方法和氮杂芳胺类化合物
AU2020240382B2 (en) * 2019-03-19 2022-08-25 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component

Similar Documents

Publication Publication Date Title
JP2022125283A5 (https=)
KR102564533B1 (ko) 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물
CN114430740A (zh) Egfr抑制剂、组合物及其制备方法
JP2024532735A (ja) 複素環式化合物及び使用方法
EP2167492B1 (en) Novel amide derivative for inhibiting the growth of cancer cells
WO2022157629A1 (en) Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer
SA519410722B1 (ar) N2، n4-مشتق ثنائي فينيل بيريميدين- ۲، ٤-ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه
AR119209A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
RU2009125897A (ru) Ингибиторы фосфоинозитид-3-киназы и способы их применения
RU2018134981A (ru) Конъюгаты, содержащие ингибиторы RIPK2
JP2010512338A5 (https=)
IL151626A (en) Quinazoline compounds, the process for their preparation, pharmaceutical preparations containing them and their use in the manufacture of drugs to create an anti-vascular formation effect and / or an effect that reduces vascular permeability in a warm-blooded animal
JP2010510319A5 (https=)
JP2020505454A5 (https=)
JP2012501312A5 (https=)
JP2019517596A5 (https=)
WO2001066099A2 (en) Use of quinazoline derivatives as angiogenesis inhibitors
WO2015015318A4 (en) Novel quinazolinones as bromodomain inhibitors
RU2006121337A (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
JP2010270154A (ja) N4−フェニルキナゾリン−4−アミン誘導体の製造方法およびその中間体
JP2020504747A5 (https=)
JP2021523177A5 (https=)
JP2018525377A5 (https=)
KR20240046090A (ko) 표적 단백질 분해를 위한 화합물 및 이의 용도
MXPA06001395A (es) Derivados de quinazolina en la forma de inhibidores de angiogenesis.